



OPEN ACCESS

ORIGINAL RESEARCH

Loss of hepatic Mboat7 leads to liver fibrosis

Veera Raghavan Thangapandi,^{1,2} Oskar Knittelfelder ,³ Mario Brosch,^{1,2} Eleonora Patsenker,⁴ Olga Vvedenskaya,³ Stephan Buch,^{1,2} Sebastian Hinz,⁵ Alexander Hendricks ,⁵ Marina Nati,⁶ Alexander Herrmann,^{1,2} Devavrat Ravindra Rekhade,^{1,2} Thomas Berg,⁷ Madlen Matz-Soja,^{7,8} Klaus Huse,⁹ Edda Klipp,¹⁰ Josch K Pauling,^{10,11} Judith AH Wodke,¹⁰ Jacobo Miranda Ackerman,³ Malte von Bonin,^{1,12} Elmar Aigner,¹³ Christian Datz ,¹⁴ Witigo von Schönfels,⁵ Sophie Nehring,^{1,2} Sebastian Zeissig,^{1,2} Christoph Röcken ,¹⁵ Andreas Dahl,² Triantafyllos Chavakis,^{3,6,16,17} Felix Stickel,⁴ Andrej Shevchenko ,³ Clemens Schafmayer,¹⁸ Jochen Hampe ,^{1,2} Pallavi Subramanian⁶

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2020-320853>).

For numbered affiliations see end of article.

Correspondence to

Professor Jochen Hampe, Department of Gastroenterology, and Hepatology MK1, University Hospital Dresden, Dresden 01307, Sachsen, Germany; jochen.hampe@uniklinikum-dresden.de

JH and PS are joint senior authors.

Received 7 February 2020

Revised 22 May 2020

Accepted 23 May 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Thangapandi VR, Knittelfelder O, Brosch M, et al. *Gut* Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2020-320853

ABSTRACT

Objective The rs641738C>T variant located near the membrane-bound O-acyltransferase domain containing 7 (MBOAT7) locus is associated with fibrosis in liver diseases, including non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease, hepatitis B and C. We aim to understand the mechanism by which the rs641738C>T variant contributes to pathogenesis of NAFLD.

Design Mice with hepatocyte-specific deletion of MBOAT7 (Mboat7^{Δhep}) were generated and livers were characterised by histology, flow cytometry, qPCR, RNA sequencing and lipidomics. We analysed the association of rs641738C>T genotype with liver inflammation and fibrosis in 846 NAFLD patients and obtained genotype-specific liver lipidomes from 280 human biopsies.

Results Allelic imbalance analysis of heterozygous human liver samples pointed to lower expression of the MBOAT7 transcript on the rs641738C>T haplotype. Mboat7^{Δhep} mice showed spontaneous steatosis characterised by increased hepatic cholesterol ester content after 10 weeks. After 6 weeks on a high fat, methionine-low, choline-deficient diet, mice developed increased hepatic fibrosis as measured by picosirius staining (p<0.05), hydroxyproline content (p<0.05) and transcriptomics, while the inflammatory cell populations and inflammatory mediators were minimally affected. In a human biopsied NAFLD cohort, MBOAT7 rs641738C>T was associated with fibrosis (p=0.004) independent of the presence of histological inflammation. Liver lipidomes of Mboat7^{Δhep} mice and human rs641738TT carriers with fibrosis showed increased total lysophosphatidylinositol levels. The altered lysophosphatidylinositol and phosphatidylinositol subspecies in MBOAT7^{Δhep} livers and human rs641738TT carriers were similar.

Conclusion Mboat7 deficiency in mice and human points to an inflammation-independent pathway of liver fibrosis that may be mediated by lipid signalling and a potentially targetable treatment option in NAFLD.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of adults and 70%–80% of obese and

Significance of this study**What is already known on this subject?**

- Non-alcoholic fatty liver disease (NAFLD) results from a multifactorial pathogenesis including genetic risk factors, obesity, intestinal dysbiosis and insulin resistance.
- Membrane-bound O-acyltransferase domain containing 7 (MBOAT7) has been previously reported as a risk gene in patients with liver diseases such as alcoholic and NAFLD, hepatitis B and C. Furthermore, reduced MBOAT7 protein in liver has been associated with altered phosphatidylinositol (PI) remodelling.
- MBOAT7 deficiency in mice reshapes the hepatic levels of PI and lysophosphatidylinositol (LPI) and promotes hyperinsulinemia and hepatic insulin resistance.

diabetic individuals worldwide.¹ NAFLD encompasses a spectrum of liver pathologies from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and eventually liver cirrhosis.^{2,3} Histopathological characteristics of NASH include steatosis, ballooning, inflammation and fibrosis.^{3,4} A recent study indicated that severe fibrosis may be present in the absence of inflammation.⁵ NASH can further progress to cirrhosis, end-stage liver disease and hepatocellular carcinoma.¹

Human genetic association studies have identified variation in several genes to be associated with NAFLD pathology, such as patatin-like phospholipase domain-containing 3, transmembrane 6 superfamily member 2 and also more recently membrane-bound O-acyltransferase domain containing 7 (MBOAT7).^{4,6,7} MBOAT7, a multi-spanning transmembrane protein, participates in acyl chain remodelling of phosphatidylinositol (PI) in the Lands cycle, by adding arachidonoyl-CoA (20:4) to 1-stearoyl (18:0) lysophosphatidylinositol (LPI) thereby generating *sn*-1-stearoyl-*sn*-2-arachidonoyl

Significance of this study

What are the new findings?

- ▶ We report a hepatocyte specific deletion of MBOAT7 in mice using cre-loxP method and understanding its role in NAFLD.
- ▶ Disturbance of the PI side chain remodelling pathway in hepatocytes alone is sufficient to elicit spontaneous steatosis under steady state and fibrosis upon an induction diet—that is, hepatocytes themselves may serve as pathogenetic driver of fibrosis.
- ▶ Mboat7 deficiency in mice and humans defines a pathway to liver fibrosis that was independent of inflammation.
- ▶ Commonly implicated lipid mediators such as free fatty acids and oxylipins remain unchanged.
- ▶ Mboat7^{Δh_{ep}} mouse model closely resembles the lipidomic changes in humans with the MBOAT7 risk variant.
- ▶ The fibrotic phenotype might be driven by extracellular lipid mediators—namely LPI.

How might it impact on clinical practice in the foreseeable future?

- ▶ Targeting PI signalling may be a novel approach to the treatment of NAFLD and liver fibrosis.
- ▶ Patients carrying the MBOAT7 mutation may be prone to fibrosis development without significant hepatic inflammation.

PI species.^{8–11} The identified human risk variant, *MBOAT7* rs641738T, has been associated with alcohol-related cirrhosis, NAFLD and with inflammation and fibrosis in chronic hepatitis B and C.^{12–18}

In carriers of the rs641738C>T variant, reduced levels of MBOAT7 protein in the liver¹⁴ and hepatic-PI remodelling¹⁸ have been observed. Additionally, Mboat7 deficiency in mice reshapes the hepatic levels of PI and LPI and promotes hyperinsulinemia and hepatic insulin resistance.^{19,20} However, the mechanisms by which the rs641738C>T variant leads to NAFLD development and especially hepatic fibrosis are not sufficiently understood. Human genetic data on MBOAT7 point to a strong association of fibrosis across a range of different liver diseases.^{13,14,16–18} Since fibrosis is the key prognostic marker for NAFLD²¹ and the

endpoint of many current clinical studies on NASH,^{22,23} investigation of Mboat7-related disease pathways holds promise to provide additional insight into fibrosis progression of chronic liver disease.

Here, we present a combined analysis of a mouse model with hepatocyte-specific *Mboat7* deletion with genetic and lipidomic analysis of human liver biopsies across the spectrum of NAFLD. We demonstrate that hepatocyte-specific deletion of *Mboat7* in mice is sufficient to cause hepatic-steatosis at steady-state. On nutritional triggering with an NASH-inducing diet, MBOAT7 deficiency resulted in a lipid-driven and inflammation-independent pathway towards liver fibrosis.

MATERIALS AND METHODS

Human NAFLD cohort

A total of 846 adult Caucasian NAFLD patients from tertiary referral centres in Austria (n=258), Germany (n=537) and Switzerland (n=51) who underwent percutaneous or surgical liver biopsy were included into this study (online supplementary tables 1–2). NASH was defined by the NAFLD Activity Score. Presence of fibrosis was assessed histologically according to Kleiner classification²⁴ (stage-F0:no fibrosis; stage-F1:perisinusoidal fibrosis to portal/periportal fibrosis; stage-F2:perisinusoidal and portal/periportal fibrosis; stage-F3:bridging fibrosis). The liver biopsies were read by experienced pathologists in a blinded fashion. Portions of this NAFLD cohort have been described previously.^{25–27} All patients gave their written consent.

Human lipidomic cohort

A total of 280 human liver samples were obtained from patients in Germany, in whom an intraoperative liver biopsy was indicated on clinical grounds such as during scheduled liver resection, exclusion of liver malignancy during major oncologic surgery or assessment of liver histology during bariatric surgery. Samples were snap frozen immediately in liquid nitrogen ensuring an *ex vivo* time of less than 40 seconds. Patients with evidence of viral hepatitis, haemochromatosis or alcohol consumption >20 g/day (women) and >30 g/day (men) were excluded. For all samples, *MBOAT7* rs641738C>T genotype as well as full phenotypic and histological information²⁴ generated by a single pathologist (CR) blinded to the lipidomic analysis was available (table 1).

Table 1 Overview of the patients in the lipidomic cohort

	Normal control	Healthy obese	NAFL	Early NASH	NASH
Age	70.5 (63.5–74)	43.5 (35.3–48.0)	43 (34–52.5)	44 (34–51)	46.5 (35–51.2)
BMI	24.6 (21.7–26.3)	48.9 (44.3–52.5)	47.8 (42.2–52.7)	50.4 (44.2–54.1)	55.2 (49.6–59.2)
Sex % male	50	6.5	34.6	37.7	21.8
Fat (area in %)	≤5	≤5	>5	>5	>5
NAS score	0 (0–0)	0 (0–0)	1 (1–2)	3 (2–3)	5 (5–6)
NAS fat	0 (0–0)	0 (0–0)	1 (1–2)	2 (1–2)	3 (3–3)
NAS ballooning	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–0)	1 (1–1)
NAS inflammation	0 (0–0)	0 (0–0)	0 (0–0)	1 (1–1)	1 (1–1.25)
Fibrosis	0 (0–0)	0 (0–0)	0 (0–1)	1 (0–1)	1 (1–1)
NAFLD without fibrosis (CC/CT/TT)	NA	NA	30/49/13	9/10/6	1/4/2
NAFLD with fibrosis (CC/CT/TT)	NA	NA	11/22/10	13/7/4	7/13/3
Total MBOAT7 rs641738 (CC/CT/TT) (n=280)	10/14/6	13/17/6	41/71/23	22/17/10	8/17/5

Patients are grouped by histology using the NAS score as the main classification criteria. Values are given as median with IQR in parentheses. Additional information is provided in online supplementary tables 8 and 9.

BMI, body mass index; MBOAT7, membrane-bound O-acyltransferase domain containing 7; NA, not applicable; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD Activity Score; NASH, non-alcoholic steatohepatitis.

Phenotypic groups (table 1) were defined on the basis of clinical and histological parameters.²⁸

Mouse model

C57BL/6 mice with hepatocyte-specific deletion of *Mboat7* (*Mboat7*^{Δhep}) were derived from crossing mice with a floxed *Mboat7* allele with mice expressing Cre recombinase under the control of Albumin promoter (Albumin-Cre). *Mboat7* floxed mice, *MBOAT7*^{tm1c(KOMP)Wtsi}, were purchased from MRC Harwell, Oxford, UK. Cre negative littermate mice with *Mboat7* floxed alleles (*Mboat7*^{WT}) were used as controls. Mice were fed normal diet (Chow diet V1534-300, Ssniff Spezialdiäten) or a high-fat, methionine-low, choline-deficient diet (HFCDD, 60% kcal fat, 0.1% methionine and choline-deficient diet; A06071302, research diets composition in online supplementary table 3) ad libitum. All experiments were performed according to the German animal welfare law and approved by the Landesdirektion Sachsen, Germany.

Lipidomic analysis

Liver tissue (~25 mg) was homogenised and protein concentration was determined by BCA/Pierce 660 assay. Lipids were extracted from aliquots containing 50 μg of total protein and quantified by shotgun lipidomics, as previously described.^{29,30} Lipidomix, Berlin, performed oxylipin and free fatty acid (FFA) measurement in liver (~30 mg) using liquid chromatography electrospray ionisation tandem mass spectrometry (LC/ESI-MS/MS).³¹

Statistical analysis

Statistical analyses were performed using GraphPad software. For comparison of quantitative measurements, the Mann-Whitney U test or unpaired t test was used. Data are expressed as mean ± SE of the mean.

See online supplementary section for detailed explanation on methods. Mouse data are additionally represented in the form of dot plots (online supplementary figures 13–19)

RESULTS

Analysis of allelic imbalance

Association of *MBOAT7* rs641738C>T variant with lower mRNA expression and lower protein levels of *MBOAT7* in human liver has been reported.¹⁴ As the downregulation of *MBOAT7* might be either caused by direct effects of the genomic variation or secondary effects, we analysed the relative allelic expression of rs8736 (LD to rs641738T: $r^2=0.98$) in rs641738T heterozygous individuals. Transcripts bearing rs8736 in the 3'UTR of *MBOAT7* show a significantly ($p<0.0001$) lower expression than transcripts bearing the ancestral allele (figure 1A), thereby indicating a *cis* down-regulatory effect on the haplotype carrying the rs641738T allele.

Hepatocyte deletion of *MBOAT7* in mice results in spontaneous steatosis characterised by increased cholesterol ester content

Previous data^{13,14} and our allelic imbalance analysis in human biopsies suggest, that reduced levels of *MBOAT7* protein are the main locus-specific mechanism of contribution to NAFLD pathogenesis in rs641738C>T carriers. We, therefore, generated mice with hepatocyte-specific deletion of *Mboat7* using *loxP*-flanked ('floxed') alleles of *Mboat7* exon 5 (online supplementary figure 1A) and Cre-mediated deletion (Alb-Cre; *Mboat7*^{fl/fl} mice; hereafter referred to as *Mboat7*^{Δhep} mice).

Littermate Cre negative *Mboat7*^{fl/fl} mice were used as controls (*Mboat7*^{WT}). Efficient deletion of *Mboat7* in liver was verified at mRNA level (figure 1B and online supplementary figure 1B) and Cre-*loxP*-mediated recombination was confirmed in primary hepatocytes by genomic-PCR (online supplementary figure 1C). We analysed liver histology in 10-week-old mice which were fed a normal diet. While there was no difference in liver weight (online supplementary figure 2A), livers from *Mboat7*^{Δhep} animals contained more lipids than *Mboat7*^{WT} mice as shown by H&E and Oil red O staining (figure 1C,D). *Mboat7*^{Δhep} primary hepatocytes showed increased lipid accumulation as compared with *Mboat7*^{WT} cells, as shown by Oil red O staining (online supplementary figure 2B). Quantitative lipidomic analysis revealed the presence of steatosis in the *Mboat7*^{Δhep} livers and primary hepatocytes was associated with the accumulation of cholesteryl esters (CEs) but not triglycerides (TAGs) (figure 1E, online supplementary figure 2C). Specifically, CE 16:1, CE 16:0, CE 18:2 and CE 18:1 were significantly increased in *Mboat7*^{Δhep} livers (online supplementary figure 2D). Flow cytometry analysis revealed no differences in the number of non-parenchymal cells (NPCs), monocytes, macrophages and neutrophils between *Mboat7*^{Δhep} and *Mboat7*^{WT} livers (figure 1F–I, online supplementary figure 2E–G). Quantitative real time PCR (qRT-PCR) analysis showed that mRNA expression of interferon-γ (IFN-γ), tumour necrosis factor α (TNF-α), interleukin-1 (IL1)-β and IL6 were unaltered between the two groups (online supplementary figure 2H). Protein levels of inflammatory mediators in the liver were unaltered between two groups (online supplementary figure 2I).

RNA sequencing of livers from *Mboat7*^{WT} and *Mboat7*^{Δhep} mice fed a normal diet was performed. Eighty-eight genes were significantly downregulated and 98 genes were significantly upregulated following *Mboat7* deletion (online supplementary table 4). Gene set enrichment analysis (GSEA) revealed a negative correlation between genes involved in fatty acid metabolism and hepatocyte specific *Mboat7* deficiency (online supplementary figure 3A). Fatty acid oxidation-related genes such as *Acaa1a*, *Acox1*, *Cpt1a*, and *Ehhadh* were diminished and a lipogenic gene, *Scd1* was upregulated in *Mboat7*^{Δhep} livers (online supplementary figure 3B). Significantly altered genes from RNA sequencing, involved in fatty acid metabolism and cholesterol (Chol) metabolism were confirmed by qRT-PCR (online supplementary figure 3C). Furthermore, *Angptl3*, which is involved in lipoprotein metabolism was upregulated in *Mboat7*^{Δhep} livers (online supplementary figure 3B and D); however, the circulating levels of *Angptl3* protein was unaltered between the two groups (online supplementary figure 3E). GSEA revealed a positive correlation between genes involved in production of extracellular matrix (ECM) and *Mboat7* deficiency (figure 1J).

Mboat7 deficiency promotes hepatic fibrosis on a high fat, methionine-low, choline-deficient diet in an inflammation independent manner

Mice were fed a HFCDD for 6 weeks to induce NAFLD. Both *Mboat7*^{Δhep} and *Mboat7*^{WT} mice accumulated lipids and showed no difference in liver weight (figure 2A,B). Although there was no visible difference in hepatic-lipid accumulation (figure 2B), *Mboat7*^{Δhep} livers accumulated more CE with no changes in TAG levels (figure 2C). CE 16:1, CE 16:0, CE 18:3, CE 18:2, CE 18:1, CE 18:0, CE 20:5 and CE 20:3 species were elevated in *Mboat7*^{Δhep} livers (online supplementary figure 4A).




Figure 1 Allelic imbalance and spontaneous steatosis phenotype of *Mboat7*^{Δhep} in 10 weeks old mice fed with normal diet. (A) Relative allelic hepatic mRNA expression of *MBOAT7* transcripts in rs641738C>T heterozygous individuals using the cSNP rs8736 that is in LD to rs641738T. Shown is the ratio of mutation carrying transcripts compared with transcripts bearing the ancient allele (left column). DNA (right column) was used as a control. n=37. (B–J) Data derived from *Mboat7*^{WT} and *Mboat7*^{Δhep} mice which were fed a normal diet. Data are presented as mean±SEM. **P<0.01 (Mann-Whitney U test). (B) mRNA expression of *Mboat7* was determined by qRT-PCR in *Mboat7*^{WT} (n=6) and *Mboat7*^{Δhep} (n=7) mice. (C) H&E staining of livers from 10-week-old *Mboat7*^{WT} and *Mboat7*^{Δhep} mice. (D) Oil red O staining of livers from 10-week-old *Mboat7*^{WT} and *Mboat7*^{Δhep} mice. Scale bars, 100 μm. (E) Hepatic-concentrations of triglyceride (TAG) and cholesterol ester (CE) (n=5 mice). (F–I) Flow cytometry analysis was performed in non-parenchymal cells (NPCs). (F) Total number of NPCs (n=6–7 mice). (G–I) Hepatic number of monocytes (CD45⁺/Ly6G⁺/CD11b⁺/F4/80⁻), macrophages (CD45⁺/Ly6G⁺/CD11b⁺/F4/80⁺) and neutrophils (CD45⁺/Ly6G⁺/CD11b⁺) in livers of *Mboat7*^{WT} and *Mboat7*^{Δhep} mice (n=6–7 mice). (J) liver RNA sequencing in *Mboat7*^{WT} and *Mboat7*^{Δhep} mice. GSEA shows a positive correlation between ECM related genes and *Mboat7* deficiency. qRT-PCR, quantitative real time-polymerase chain reaction; CE, cholesteryl ester; ECM, extracellular matrix; GSEA, gene set enrichment analysis; LD, linkage disequilibrium; *MBOAT7*, membrane-bound O-acyltransferase domain containing 7; NS, not significant; SEM, SE of the mean.

In the *Mboat7*^{Δhep} mice we observed increased aspartate transaminase (AST) activity (online supplementary figure 4B) and alanine aminotransferase (ALT) activity showed a non-significant trend towards increase in *Mboat7*^{Δhep} mice (online supplementary figure 4C). Increased fibrosis was assessed by picrosirius red staining and western blot for TIMP1 in *Mboat7*^{Δhep} mice (figure 2D,E and online supplementary figure 4D). The hepatic-hydroxyproline concentrations were increased by ~45% in the *Mboat7*^{Δhep} as compared with *Mboat7*^{WT} livers (p=0.031, figure 2F). On liver mRNA

sequencing, 466 genes were upregulated and 112 genes were downregulated in *Mboat7*^{Δhep} livers following HFCDD feeding (online supplementary table 5). In accordance with the picrosirius red and hydroxyproline measurements, pathways related to ECM, extracellular structure organisation, wound healing and tissue remodelling were significantly upregulated in *Mboat7*^{Δhep} livers (figure 2G and online supplementary figure 5A). GSEA analysis showed a positive correlation between genes involved in production of ECM and *Mboat7* deletion (figure 2H). Transcripts




Figure 2 Mboat7-deficiency promotes hepatic fibrosis in mice on a high fat, methionine-low, choline-deficient diet in an inflammation independent manner. (A, C, D, F, J–L) data derived from Mboat7^{WT} and Mboat7^{Δhep} which were fed a HFCDD for 6 weeks. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01. (Mann-Whitney U test). (A) liver weight of Mboat7^{WT} and Mboat7^{Δhep} mice (n = 7–8 mice). (B) H&E staining. Scale bars, 200 μm. (C) Hepatic-concentrations of TAG and CE (n = 7–8 mice). (D, E) quantification (D) and representative images (E) of picrosirius red positive area in livers of Mboat7^{WT} and Mboat7^{Δhep} mice. Scale bars, 100 μm. (n = 7–8 mice). (F) quantification of hydroxyproline (n = 4–5 mice). (G–I) RNA sequencing results in livers of Mboat7^{WT} and Mboat7^{Δhep} mice. (G) heat map of significantly upregulated genes (FDR < 0.05) in Mboat7^{Δhep} livers from the extracellular matrix organisation pathway (from online supplementary figure 5A). (H) GSEA shows a positive correlation between the extracellular matrix related genes and Mboat7 deficiency. (I) heat map of collagen subtypes that were significantly (FDR < 0.05) upregulated in the Mboat7^{Δhep} livers. (J) qRT-PCR results (n = 4–5 mice). (K, L) flow cytometry analysis of NPCs, (total NPCs, monocytes, macrophages, neutrophils, CD4, CD8 T cells) isolated from livers of Mboat7^{WT} and Mboat7^{Δhep} mice. (n = 4–5 mice). CE, cholesteryl ester; GSEA, gene set enrichment analysis; HFCDD, high-fat, methionine-low, choline-deficient diet; MBOAT7, membrane-bound O-acyltransferase domain containing 7; FDR, False discovery rate; NPCs, non-parenchymal cells; SEM, SE of the mean; TAG, triglyceride.

of collagen subtypes such as *Col6a3*, *Col4a5*, *Col4a4*, *Col6a1*, *Col6a2*, *Col1a2*, *Col1a1*, *Col3a1*, *Col5a2*, *Col15a1*, *Col8a1* and *Acta2* were elevated in the Mboat7^{Δhep} livers (figure 2I and online supplementary figure 5B). Several ECM-related genes were further confirmed by qRT-PCR with consistent results (figure 2J). Various lipid metabolic pathways and ‘inflammatory response’ pathways were downregulated in livers of Mboat7 deficient mice following HFCDD feeding (online supplementary figure 5C).

Intriguingly, there were no differences in the number of NPCs, macrophages, neutrophils, CD4 T cells and CD8 T cells between the two groups on flow cytometry analysis (figure 2K,L). Nominal numbers of monocyte population were reduced in Mboat7^{Δhep} livers (figure 2L). However, the percentage of inflammatory cells were unchanged (online supplementary figure 5D). Inflammatory mediators such as TNF-alpha, IL6, IL1-beta and IFN-gamma were all unchanged at the mRNA level (online supplementary figure

5E) and on mRNA sequencing (data not shown). Protein levels of TNF- α and KC/GRO were increased and IL2 was decreased in Mboat7^{Δhep} livers, whereas IFN γ , IL1 β , IL4, IL5, IL6, IL10 and IL12p70 were unaltered between the two groups (online supplementary figure 5F). Markers of ER stress were not altered in the Mboat7^{Δhep} liver (online supplementary figure 6A–K).

The MBOAT7 rs641738C>T variant is associated with hepatic fibrosis in humans with a body mass index ≤ 35 independent of the presence of inflammation

We analysed the frequency of the rs641738C>T allele in patients (separately in body mass index (BMI) ≤ 35 and BMI > 35) from a cross-sectional NAFLD liver biopsy cohort stratified by the presence of liver fibrosis and lobular inflammation. In patients with BMI ≤ 35 , the rs641738C>T allele was significantly associated with the presence of fibrosis (F1–F4) in the absence of lobular inflammation ($p=0.001$; OR=1.91 (1.27–2.87), figure 3A). In the presence of lobular inflammation (1–3), the association of the rs641738C>T allele with the presence of fibrosis yielded a similar odds ratio ($p=0.289$; OR=1.70 (0.64–4.56)), suggesting the development of fibrosis may be independent of inflammation in patients carrying the rs641738C>T variant (figure 3A). Interestingly, in morbidly obese patients with a BMI > 35 , no association of rs641738C>T genotype with the presence of histological fibrosis was observed (figure 3B).

Mboat7^{Δhep} mice do not exhibit altered hepatic levels of FFA and oxylipins

As Mboat7 functions by adding arachidonoyl-CoA (20:4) to 1-stearoyl (18:0) LPI (online supplementary figure 7),^{9, 32, 33} we hypothesised that Mboat7 deficiency could lead to altered levels of FFA and fatty acid metabolites (oxylipins) in the liver. Therefore, we measured the hepatic concentrations of FFA and oxylipins in Mboat7^{WT} and Mboat7^{Δhep} mice. We found no significant differences in the levels of FFA between the two groups both on a normal diet and on HFCDD feeding (figure 3C,D). On correction for multiple testing across both diets, there was no difference in the hepatic oxylipin concentrations between the Mboat7^{WT} and Mboat7^{Δhep} mice on normal diet (online supplementary table 6) and after HFCDD (online supplementary table 7).

Lipidomic analysis of PI and LPI species in mouse liver

Given the biochemical function of Mboat7^{9, 32, 33} (online supplementary figure 7), hepatocyte-specific knockout of the enzyme might have an impact on the molecular composition and molar abundance of LPI and PI. In normal diet fed mice, total LPI levels were increased from 0.59 ± 0.11 pmol/ μ g of total protein in Mboat7^{WT} livers to 2.72 ± 0.26 pmol/ μ g in Mboat7^{Δhep} livers (figure 4A). LPI 20:4 was diminished in Mboat7^{Δhep} livers while LPI 16:0, LPI 18:1 and LPI 18:0 were increased (figure 4A,B). Of note, LPI 18:1 was not detected in Mboat7^{WT} but was induced in Mboat7^{Δhep} livers (figure 4B). Total PI levels were reduced in Mboat7^{Δhep} livers (figure 4A). As reported previously, PI 38:4 was the most abundant PI species accounting for 88% of total PI in Mboat7^{WT} livers (data not shown).¹⁹ PI 38:4 was strikingly down-regulated with $\sim 60\%$ reduction in Mboat7^{Δhep} livers as compared with Mboat7^{WT} livers (figure 4C). In addition to PI 38:4, PI 36:4 and PI 38:5 were also significantly reduced in the Mboat7^{Δhep} livers (figure 4C). In addition to PI and LPI, phosphatidylglycerol (PG), lysophosphatidylglycerol (LPG) and phosphatidic acid (PA) were elevated in the livers of Mboat7 deficient as compared with Mboat7 sufficient mice (figure 4A). The hepatic levels of other phospholipid classes such as PC, PE, PS, PC-O and lysophospholipids such

as lysophosphatidylethanolamine (LPE) and lysophosphatidylcholine (LPC), ceramides, sphingomyelin (SM), diacylglycerol and Chol were unaltered (figure 4A). In order to identify alterations in the hepatocyte lipidome, we performed lipidomic analysis in isolated primary hepatocytes from Mboat7^{WT} and Mboat7^{Δhep} mice (online supplementary figure 8A). Similar to total liver, we found that LPI and PG levels were enhanced in Mboat7^{Δhep} hepatocytes as compared with Mboat7^{WT} hepatocytes (online supplementary figure 8A), demonstrating that the significant alterations observed in the liver lipidome (figure 4A) mainly originated from the hepatocytes.

In mice fed the HFCDD demonstrating the fibrotic liver phenotype, key phospholipids were also altered (figure 4D–F): Total LPI levels and LPI species LPI 16:0, LPI 18:1 and LPI 18:0 were increased in Mboat7^{Δhep} livers (figure 4D–E). LPI 18:1 was not detected in Mboat7^{WT} livers but was upregulated following hepatocyte-specific Mboat7 deletion (figure 4E). Other phospholipids and lysophospholipids such as PG, LPG, PC, PE, PS, PE O-, PC O-, LPE, LPC and SM were also increased in Mboat7^{Δhep} livers during NAFLD (figure 4D). PI 38:4 was significantly reduced, whereas PI 34:2, PI 36:3, PI 36:2, PI 38:6, PI 40:7, PI 40:6 and PI 40:5 were increased in Mboat7^{Δhep} livers as compared with Mboat7^{WT} livers (figure 4F).

Lipidomic analysis of human liver biopsies

We performed a lipidomic analysis in a cross-sectional liver biopsy cohort (table 1) stratified by the rs641738C>T genotype. Except for cardiolipin, we found no differences in total amounts of lipid classes between CC, CT and TT groups (figure 5A–C). In individuals carrying the rs641738TT risk genotype, profound remodelling of PI species was observed, specifically PI 32:0, PI 32:1, PI 34:1, PI 34:2, PI 36:1, PI 36:2, PI 38:6, PI 40:5 and PI 40:6 were elevated in the TT group compared with the CC group, whereas PI 40:4, PI 36:4 and PI 38:4 were reduced in the TT group (figure 5D,E). The decrease of PI 38:4 in rs641738TT samples was also observed when stratified for disease condition, specifically in NAFL, early NASH and NASH samples (online supplementary figure 9A). Furthermore, LPI 18:0 levels were increased ($p=0.002$) and LPI 20:4 levels were decreased ($p=0.009$) in the TT group as compared with the CC group (figure 5F). By stratifying for presence or absence of fibrosis, we found that total LPI levels were positively correlated with rs641738TT genotype only in the presence of fibrosis (figure 5G). Additionally, LPA levels were also correlated with the rs641738TT genotype only in the presence of fibrosis, whereas other lipid classes were unaltered (online supplementary figure 9B–D). In the absence of fibrosis, no alterations were found in the CC as compared with the TT groups (online supplementary figure 9E–G). Changes in molecular composition of PI and LPI species were remarkably similar between humans homozygous for the MBOAT7 rs641738TT risk variant and Mboat7 deficient mice under normal diet and after HFCDD feeding (figure 5H–M). On stratifying for both, the MBOAT7 rs641738C>T genotype and disease condition, we observed significant first broad changes between phenotypic groups in lipid class compositions (online supplementary figure 10A–O). Alterations in lipid classes in the MBOAT7 genotype-specific analysis were observed in the normal control, NAFL, early NASH and NASH groups, whereas no differences were found in the healthy obese group. Consistent with the highest proportion of samples with histological fibrosis, genotype-specific lipid class alterations were most pronounced in the NASH group (online supplementary figure 10M–O). Lipidomic comparison of fibrotic and non-fibrotic NAFL revealed significant genotype-specific alterations in lysolipids LPI and LPA (online




Figure 3 The MBOAT7 rs641738T variant associates with fibrosis independent of inflammation. Hepatic Mboat7 deficiency is not associated with altered free fatty acids in mice. (A, B) the frequency of the MBOAT7 rs641738C>T allele in NAFLD patients (A) BMI ≤35 (without inflammation, F0, n=215; without inflammation, F1-4, n=74; with inflammation, F0, n=10; with inflammation, F1-4, n=62) and (B) BMI >35 (without inflammation, F0, n=231; without inflammation, F1-4, n=96; with inflammation, F0, n=64; with inflammation, F1-4, n=94) from a cross-sectional liver biopsy cohort, stratified by the presence of liver fibrosis and lobular inflammation. Genetic analyses were calculated using an additive model. Differences between the groups were compared by logistic regression analysis adjusted for sex, age, BMI and presence of T2DM (online supplementary table 1 & 2). (C, D) hepatic free-fatty acid levels on normal diet (C) and HFCDD diet (D). Data are presented as mean±SEM. (n=6–8 mice). BMI, body mass index; HFCDD, high-fat, methionine-low, choline-deficient diet; MBOAT7, membrane-bound O-acyltransferase domain containing 7; NAFLD, non-alcoholic fatty liver disease; T2DM, Type 2 Diabetes mellitus; MAF, Minor allele frequency; SEM, SE of the mean.

supplementary figure 9B–G). Results were robust to exclusion of patients on statin medication (n=14) as shown in online supplementary figure 11A–C.

DISCUSSION

NAFLD encompasses a broad phenotypic spectrum from benign steatosis to liver cirrhosis and liver-related death.²³ The strongest and ultimately sole prognostic factor for liver-related mortality

is the presence and progression of fibrosis. Interestingly, fibrosis can occur in up to 30% of patients without relevant inflammation.⁵ In contrast to its clinical and prognostic relevance, the process of fibrogenesis in the context of NAFLD is poorly understood. Discovery of the MBOAT7 locus, which is associated with a strong fibrotic signature in human NAFLD, alcoholic liver disease and infectious hepatitis,^{13 14 16 17} raised expectations




Figure 4 Lipidomic analysis of mouse liver on normal and HFCDD diet. (A–F) data are presented as mean±SEM. (Mann-Whitney U test). *P<0.05, **P<0.01, ***P<0.001. lipidomic analysis of livers on a normal diet (A–C, n=5 mice) and HFCDD diet (D–F, n=7–8 mice). Cer, ceramides; Chol, cholesterol; DAG, diacylglycerol; HFCDD, high-fat, methionine-low, choline-deficient diet; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LPG, lysophosphatidylglycerol; LPI, lysophosphatidylinositol; MBOAT7, membrane-bound O-acyltransferase domain containing 7; ND, not detected; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; SEM, SE of the mean; SM, sphingomyelin.

for uncovering novel mechanisms underlying hepatic fibrogenesis of broad relevance. Here, we provide a combined mouse and human dataset that advances our knowledge pertinent to NAFLD-related fibrosis and at the same time challenges several central paradigms of current NAFLD research.

We demonstrate that a disrupted PI remodelling pathway in hepatocytes is associated with phenotypes on standard and a NASH-inducing diet: *Mboat7*^{Δhep} mice developed spontaneous steatosis on normal diet. Steatosis was characterised by increased Chol esters while TAGs were unchanged. The lipogenic enzyme, *Scd1* (*SCD1*, stearoyl-CoA desaturase) was upregulated and several fatty acid oxidation genes were down-regulated in *Mboat7* deficient livers at steady state. The major product of *SCD1* is oleic acid (18:1) which is the preferred substrate for acyl-CoA:cholesterol acyltransferase, the Chol esterification enzyme.^{34 35} The reduced fatty-acid oxidation and increased *SCD1* may at least partly explain the increased CE levels and spontaneous steatosis seen in *Mboat7*-deficient livers, however, further investigation is required to completely understand the mechanisms involved. Similar to the current study, it was shown recently that silencing *Mboat7* in mice using

antisense oligonucleotide conjugated with morpholinos results in spontaneous lipid accumulation in the liver; however, the study concludes that this was due to increased TAG accumulation although CE levels were not measured in their samples.³⁶ Another study, in which antisense oligonucleotides were used to knock down *Mboat7* in adipose tissue, liver and cells of the reticuloendothelial system reported no spontaneous phenotype.²⁰ However, following high-fat diet (HFD) feeding, these mice exhibited elevated levels of TAGs and CEs in the liver.²⁰ The phenotypic differences seen between these previous studies and the current study might be explained by the broader knock-down of *Mboat7* using the antisense oligonucleotide approach.^{20 36}

Disturbed lipid metabolism in hepatocytes is sufficient to drive liver fibrosis

After HFCDD feeding, *Mboat7*^{Δhep} mice developed increased hepatic-fibrosis as measured by picosirius staining and relative hepatic hydroxyproline content and transcriptomic analysis revealed a broad upregulation of ECM genes. Thus, disturbance of the PI side chain remodelling pathway in hepatocytes elicits fibrosis on an induction diet—that is, hepatocytes themselves may serve as a pathogenic driver of fibrosis.

***Mboat7*-deficiency elicits liver fibrosis in the absence of inflammation**

We found that, the *MBOAT7* risk variant was associated with hepatic fibrosis independent of the presence of inflammation. This represents an intriguing and novel mechanism for liver fibrosis, suggesting that hepatocyte signalling in the fibrogenic mesenchymal cell compartment, that is, primarily myofibroblasts/hepatic stellate cells, is sufficient to induce fibrosis without an increased inflammatory infiltrate. Mancina *et al* have shown that *MBOAT7* rs641738C>T is associated with more necroinflammation.¹⁴ In mice, Helsley *et al* have shown that HFD feeding of *Mboat7* deficient mice results in reduced hepatic-accumulation of total macrophages and M2 macrophages, whereas, CD8+T cells and M1 macrophages were increased.²⁰ Differences in the inflammatory cell accumulation seen between the current study and the study by Helsley *et al* may be due to the strategy they used for *Mboat7* deletion (antisense oligonucleotide) which is known to silence *Mboat7* in adipose tissue, liver and cells of the reticuloendothelial system, which includes macrophages; therefore, these changes in inflammatory cells could derive from the loss of macrophage-specific *Mboat7* function.²⁰ Moreover, in the study by Helsley *et al*, mice were treated with the antisense oligonucleotide to silence *Mboat7* concurrently during HFD feeding, therefore, *Mboat7* was not silenced before the start of the feeding.

FFA and oxylipins are unchanged in the fibrotic mouse phenotype

Since *Mboat7* exhibits LPI acyltransferase activity towards arachidonoyl-CoA,⁸ deletion of *Mboat7* could lead to elevated levels of free arachidonic acid and the generation of its proinflammatory lipid metabolites. However, we found no significant increase in FFA and oxylipins in *Mboat7*^{Δhep} mice, suggesting that these lipid mediators and arachidonic acid-derived metabolites do not contribute to fibrosis development in this model. These findings are concordant to a recent study that has shown that arachidonic acid-derived proinflammatory lipid mediators were not altered in the livers of *Mboat7* deficient mice.^{20 37} Because FFA and fatty acid metabolites are known proinflammatory




Figure 5 Lipidomic analysis of human liver biopsies stratified by MBOAT7 rs641738C>T genotype. (A–E) lipidomic analysis of human livers (lipidomic cohort) stratified by rs641738C>T genotype (not grouped for a disease condition, age, sex, and BMI). Data are presented as mean±SEM, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Patient samples in which a specific lipid class was not detected were excluded from analysis. Alterations in PI and LPI species are presented as mol% (% of total PI and % of total LPI). (A) alterations in hepatic triglyceride (TAG) levels. CC, $n = 94$; CT, $n = 136$; TT, $n = 50$. (B) alterations in hepatic lipid classes. CC, $n = 94$; CT, $n = 136$; TT, $n = 50$. (C) alterations in hepatic lipid classes. CER, ceramide (CC, $n = 94$; CT, $n = 136$; TT, $n = 50$); CL*, cardiolipin (CC, $n = 55$; CT, $n = 87$; TT, $n = 24$); LPA*, lyso-phosphatidate (CC, $n = 45$; CT, $n = 56$; TT, $n = 11$); LPC, lysophosphatidylcholine (CC, $n = 94$; CT, $n = 136$; TT, $n = 50$); LPE, lysophosphatidylethanolamine (CC, $n = 94$; CT, $n = 136$; TT, $n = 50$); LPG*, lysophosphatidylglycerol (CC, $n = 87$; CT, $n = 123$; TT, $n = 48$); LPI*, lysophosphatidylinositol (CC, $n = 85$; CT, $n = 120$; TT, $n = 48$); LPS*, lysophosphatidylserine (CC, $n = 91$; CT, $n = 132$; TT, $n = 48$). *Patient samples in which a specific lipid class was not detected were excluded from analysis. (D) Alterations in PI species presented as mol% (% of total PI). CC, $n = 94$; CT, $n = 136$; TT, $n = 50$. (E) Alterations in PI species presented as mol% (% of total PI). *PI 32:0 (CC, $n = 68$; CT, $n = 103$; TT, $n = 37$); *PI 32:1 (CC, $n = 54$; CT, $n = 59$; TT, $n = 30$); *PI 34:0 (CC, $n = 87$; CT, $n = 116$; TT, $n = 37$); *PI 34:1 (CC, $n = 92$; CT, $n = 128$; TT, $n = 46$); *PI 34:2 (CC, $n = 93$; CT, $n = 130$; TT, $n = 46$); *PI 36:1 (CC, $n = 93$; CT, $n = 136$; TT, $n = 50$); *PI 38:3 (CC, $n = 3$; CT, $n = 7$; TT, $n = 3$); *PI 38:6 (CC, $n = 92$; CT, $n = 128$; TT, $n = 50$); *PI 40:4 (CC, $n = 34$; CT, $n = 41$; TT, $n = 11$); *PI 40:7 (CC, $n = 27$; CT, $n = 32$; TT, $n = 19$). *Patient samples in which a specific lipid species was not detected were excluded from analysis. (F) Alterations in LPI species presented as mol% (% of total LPI). CC, $n = 10$; TT, $n = 7$. (analysis was done on patient liver samples in which 4 LPI species were detected). (G) comparison of total LPI level in NAFLD (include NAFL, early NASH and NASH samples) patient livers with and without the presence of fibrosis. with fibrosis, CC, $n = 25$; with fibrosis, TT, $n = 17$; without fibrosis, CC, $n = 39$; without fibrosis, TT, $n = 20$. NS, not significant. (Patient samples in which no LPI species was detected were excluded). (H–M) Difference of means of common PI and LPI species (mol%) in mice and humans. (H, K) Lipidomic analysis of human livers obtained from people with either the CC or TT genotype (not grouped for a disease condition, age, sex, and BMI), (I, L) livers from Mboat7^{WT} and Mboat7^{Δhep} mice fed a normal diet and (J, M) livers from Mboat7^{WT} and Mboat7^{Δhep} mice fed an HFCDD for 6 weeks. (H, K) Difference of means (mol% values, TT-CC) of PI and LPI species in human livers. (I, L) Difference of means (mol% values) of PI and LPI species in Mboat7^{WT} and Mboat7^{Δhep} mice fed a normal diet (Mboat7^{Δhep} - Mboat7^{WT}). $n = 5$ mice. (J, M) Difference of mean (mol% values) of PI and LPI species in Mboat7^{WT} and Mboat7^{Δhep} mice fed an HFCDD (Mboat7^{Δhep} - Mboat7^{WT}). $n = 7$ –8 mice. BMI, body mass index; DAG, diacylglycerol; NAFL, non-alcoholic fatty liver; MBOAT7, membrane-bound O-acyltransferase domain containing 7; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.

mediators^{38–40} this finding is consistent with the lack of changes in the lobular inflammatory compartment.

Resemblance of human NAFLD and the mouse model

Interestingly, the lipidomic changes associated with hepatocyte-specific Mboat7 deficiency closely resemble the lipidomic alterations in humans with the MBOAT7 risk variant and may thus represent a promising model to gain further insights into the patients with NAFLD fibrosis, although all NAFLD patients in this study were recruited from bariatric surgery. Furthermore, murine and human data are in agreement with regard to the genetic association of *MBOAT7* genotype with fibrosis and inflammation: We show that the correlation between the rs641738C>T variant and hepatic-fibrosis was indeed independent of inflammation in our biopsied NAFLD patients with a BMI≤35.

Novel lipid signalling targets in NAFLD

Mboat7 functions in the Lands' cycle, where it adds arachidonic acid (20:4) to 1-stearoyl (18:0) LPI thereby generating *sn*-1-stearoyl-*sn*-2-arachidonoyl PI species,⁹ which in turn might lead to increased LPI levels and an altered PI spectrum if Mboat7 is absent in liver. In the absence of Mboat7, alterations in PI species have been reported in mice, humans and in cultured hepatocytes, previously.^{14 18 19 36} We confirm and extend these findings through broader and liver-specific lipidomics in mice and humans and observe characteristic genotype-specific alterations in lysolipid patterns between fibrotic and non-fibrotic NAFL (online supplementary figure 9B–G, figure 5G). Intriguingly, the lipidomic patterns in mouse Mboat7^{Δhep} livers and humans carrying the rs641738TT variant showed striking similarities. We demonstrate a profound remodelling of PI with a reduction of PI species containing arachidonoyl side chains and increase of other PI species particularly with monounsaturated fatty acids. Increased LPI levels and particularly LPI 18:0 correlated with the presence of fibrosis in the human rs641738TT genotype and in the murine fibrotic phenotype. LPI is exported from cells via ABCG1,^{41–43} thereby rendering it a candidate profibrotic lipid mediator, which might directly interact with the stellate cell compartment. Circulating LPI levels are significantly increased in patients with liver fibrosis as compared with healthy people²⁰ and treating obese mice with exogenous LPI 18:1 promotes pro-fibrotic gene expression in the liver.²⁰ LPI might thus play a signalling role in fibrosis development.

In summary, our combined murine and human data provide novel insights into NAFLD pathogenesis (online supplementary figure 12). Further mechanistic studies of the new candidate lipid mediators and their effects on other hepatic cell populations are required to provide a deeper understanding of these pathways and to transform them into viable target molecules.

Author affiliations

¹Department of Medicine I, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany

²Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, Dresden, Germany

³Max-Planck-Institute of Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany

⁴Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland

⁵Department of Visceral and Thoracic Surgery, Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany

⁶Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany

⁷Division of Hepatology, Department of Oncology, Gastroenterology, Hepatology Pulmonology, and Infectious Diseases, University Hospital Leipzig, Leipzig, Sachsen, Germany

⁸Rudolf Schönheimer- Institute of Biochemistry, University of Leipzig Faculty of Medicine, Leipzig, Germany

⁹Leibniz Institute for Age Research Fritz-Lipmann Institute, Jena, Thüringen, Germany

¹⁰Department of Theoretical Biophysics, Institute of Biology, Humboldt-Universität zu Berlin, Berlin, Germany

¹¹LipiTUM, Chair of Experimental Bioinformatics, TUM School of Life Sciences, Technical University of Munich, Freising, Bayern, Germany

¹²German Cancer Consortium, Heidelberg, Baden-Württemberg, Germany

¹³Department of Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria

¹⁴Department of Internal Medicine, Hospital Oberndorf, Teaching Hospital of the Paracelsus Private University of Salzburg, Obendorf, Austria

¹⁵Department of Pathology, University Hospital Schleswig Holstein, Kiel, Schleswig-Holstein, Germany

¹⁶German Center for Diabetes Research, Neuherberg, Germany

¹⁷Paul Langerhans Institute Dresden, Helmholtz Zentrum München, University Hospital Dresden, Technische Universität (TU) Dresden, Dresden, Sachsen, Germany

¹⁸Department of General, Visceral, Vascular and Transplantation Surgery, University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany

Acknowledgements The authors wish to thank all study participants, researchers, clinicians, technicians and administrative staff who contributed to this study.

Contributors Project was conceived and experiments were conceptualised by: VRT, PS, MB, EK, TC, FS, MMS, and JH. Experiments were performed by VRT, PS, OK, EP, OV, KH, MN, SN, AD, DRR and MVB. Patient sample collection and coordination was done by CS, WVS, SH, AH, TB, EA, CD and CR. Data analysis was done by VRT, PS, SB, AH, JAHW, JKP and JMA. Manuscript was written and edited by VRT, PS, JH, TC, AS, SZ and FS.

Funding This study was supported by the German Ministry of Research and Education (BmBF) through the Liver Systems Medicine (LiSyM) network grant (to JH and AS) and ERACOSysMed (Dynaflow) grant (to JH), an ERC grant (DEMETINL to TC) and Lipidomics and Informatics for Life Sciences (LIFS) grant Unit of the de. NBI Consortium (AS). Additional support came from the Swiss National Funds (grants 310030_138747/1 and 310030_169196 to F.S.) Contributions by JP were partly funded by the Bavarian State Ministry of Science and the Arts in the framework of the Centre Digitisation. Bavaria (ZDB).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval Subjects recruited for the genetic association study came from different sites, at which the study protocol was approved by the ethics committees of the participating institutions.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Not applicable.

Author note The transcriptomic data is available at GEO under id GSE139992

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Oskar Knittelfelder <http://orcid.org/0000-0002-1565-7238>

Alexander Hendricks <http://orcid.org/0000-0002-7286-9245>

Christian Datz <http://orcid.org/0000-0001-7838-4532>

Christoph Röcken <http://orcid.org/0000-0002-6989-8002>

Andrej Shevchenko <http://orcid.org/0000-0002-5079-1109>

Jochen Hampe <http://orcid.org/0000-0002-2421-6127>

REFERENCES

- Musso G, Cassader M, Gambino R. Non-Alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. *Nat Rev Drug Discov* 2016;15:249–74.
- Hardy T, Oakley F, Anstee QM, et al. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. *Annu Rev Pathol* 2016;11:451–96.
- Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med* 2018;24:908–22.
- Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis of NASH. *Int J Mol Sci* 2016;17:1575.
- Pelusi S, Cespiati A, Rametta R, et al. Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis. *Clin Gastroenterol Hepatol* 2019;17:2310–9.

- 6 Seko Y, Yamaguchi K, Itoh Y. The genetic backgrounds in nonalcoholic fatty liver disease. *Clin J Gastroenterol* 2018;11:97–102.
- 7 Scott E, Anstee QM. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. *Clin Med* 2018;18:s54–9.
- 8 Shindou H, Hishikawa D, Harayama T, et al. Recent progress on acyl CoA: lysophospholipid acyltransferase research. *J Lipid Res* 2009;50 Suppl:S46–51.
- 9 Yamashita A, Oka S, Tanikawa T, et al. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55. *Prostaglandins Other Lipid Mediat* 2013;107:103–16.
- 10 Caddeo A, Jamialahmadi O, Solinas G, et al. MBOAT7 is anchored to endomembranes by six transmembrane domains. *J Struct Biol* 2019;206:349–60.
- 11 Lee H-C, Kubo T, Kono N, et al. Depletion of *mboa-7*, an enzyme that incorporates polyunsaturated fatty acids into phosphatidylinositol (PI), impairs Pi 3-phosphate signaling in *Caenorhabditis elegans*. *Genes Cells* 2012;17:748–57.
- 12 Krawczyk M, Rau M, Schattenberg JM, et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. *J Lipid Res* 2017;58:247–55.
- 13 Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. *Nat Genet* 2015;47:1443–8.
- 14 Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. *Gastroenterology* 2016;150:1219–30.
- 15 Di Sessa A, Umamo GR, Cirillo G, et al. The membrane-bound O-Acyltransferase7 rs641738 variant in pediatric nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr* 2018;67:69–74.
- 16 Thabet K, Asimakopoulos A, Shojaei M, et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. *Nat Commun* 2016;7:1–8.
- 17 Thabet K, Chan HLY, Petta S, et al. The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. *Hepatology* 2017;65:1840–50.
- 18 Luukkonen PK, Zhou Y, Hyötyläinen T, et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. *J Hepatol* 2016;65:1263–5.
- 19 Anderson KE, Kielkowska A, Durrant TN, et al. Lysophosphatidylinositol-Acyltransferase-1 (LPIAT1) is required to maintain physiological levels of PtdIns and PtdInsP2 in the mouse. *PLoS One* 2013;8:e58425–13.
- 20 Helsley RN, Varadharajan V, Brown AL, et al. Obesity-Linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. *eLife* 2019;8.
- 21 Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2015;149:e10:389–97.
- 22 Hannah WN, Torres DM, Harrison SA. Nonalcoholic steatohepatitis and endpoints in clinical trials. *Gastroenterol Hepatol* 2016;12:756–763.
- 23 Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology* 2018;68:361–71.
- 24 Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005;41:1313–21.
- 25 Strnad P, Buch S, Hamesch K, et al. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. *Gut* 2019;68:1099–107.
- 26 Stättermayer AF, Traussnigg S, Aigner E, et al. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. *J Trace Elem Med Biol* 2017;39:100–7.
- 27 Horvath S, Erhart W, Brosch M, et al. Obesity accelerates epigenetic aging of human liver. *Proc Natl Acad Sci U S A* 2014;111:15538–43.
- 28 Brosch M, Kattler K, Herrmann A, et al. Epigenomic map of human liver reveals principles of zoned morphogenic and metabolic control. *Nat Commun* 2018;9:1–11.
- 29 Sales S, Graessler J, Ciucci S, et al. Gender, contraceptives and individual metabolic predisposition shape a healthy plasma lipidome. *Sci Rep* 2016;6:27710.
- 30 Sales S, Knittelfelder O, Shevchenko A. Lipidomics of human blood plasma by high-resolution shotgun mass spectrometry. *Methods Mol Biol* 2017;1619:203–212.
- 31 Tsikas D, Zoerner AA. Analysis of eicosanoids by LC-MS/MS and GC-MS/MS: a historical retrospect and a discussion. *Journal of Chromatography B* 2014;964:79–88.
- 32 Gijón MA, Riekhof WR, Zarini S, et al. Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. *J Biol Chem* 2008;283:30235–45.
- 33 Alhouayek M, Masquelier J, Muccioli GG. Lysophosphatidylinositols, from cell membrane constituents to GPR55 ligands. *Trends Pharmacol Sci* 2018;39:586–604.
- 34 Miyazaki M, Kim YC, Gray-Keller MP, et al. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearyl-CoA desaturase 1. *J Biol Chem* 2000;275:30132–8.
- 35 Landau JM, Sekowski A, Hamm MW. Dietary cholesterol and the activity of stearyl CoA desaturase in rats: evidence for an indirect regulatory effect. *Biochim Biophys Acta* 1997;1345:349–57.
- 36 Meroni M, Dongiovanni P, Longo M, et al. Mboat7 down-regulation by hyperinsulinemia induces fat accumulation in hepatocytes: Mboat7 reduction and hepatic steatosis. *EBioMedicine* 2020;52:102658.
- 37 Tanaka Y, Shimanaka Y, Caddeo A, et al. LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. *Gut* 2020;gutjnl-2020-320646. doi:10.1136/gutjnl-2020-320646. [Epub ahead of print: 06 Apr 2020].
- 38 Loomba R, Quehenberger O, Armando A, et al. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. *J Lipid Res* 2015;56:185–92.
- 39 López-Vicario C, Rius B, Alcaraz-Quiles J, et al. Pro-Resolving mediators produced from EPA and DHA: overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. *Eur J Pharmacol* 2016;785:133–43.
- 40 Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. *Hepatology* 2009;50:1827–38.
- 41 Piñero R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. *Oncogene* 2011;30:142–52.
- 42 Hu G, Ren G, Shi Y. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. *Oncogene* 2011;30:139–41.
- 43 Andradas C, Caffarel MM, Pérez-Gómez E, et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. *Oncogene* 2011;30:245